We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Ocular Gel Seals Corneal Incision After Cataract Surgery

By HospiMedica International staff writers
Posted on 29 Jan 2014
An innovative gel sealant could replace stitches for stopping fluid leakage through the incision used for intraocular lens placement in adults.

The ReSure Sealant is a patented polyethylene glycol-based (PEG) hydrogel, which is applied as a liquid and gels on the surface of the eye in less than 20 seconds. More...
Once the ReSure material gels, it remains localized over the incision to seal the wound and form a lubricious surface barrier. The hydrogel contains a blue visualization aid to assist with placement over the incision, which dissipates within hours of application. The material is designed to stay on the incision in the immediate postoperative period when wounds are most vulnerable, after which it gently sloughs off in the patient’s tears.

The sealant was evaluated against sutures in a prospective, controlled, randomized, multicenter clinical trial for prevention of fluid egress in clear corneal incisions. ReSure demonstrated superiority over sutures by successfully preventing wound leaks in 95.9% of cases, compared to sutures in only 65.9% of cases. The ReSure Sealant also demonstrated significantly fewer device-related adverse events than the control group, at 1.6% versus 30.6% for sutures. ReSure Sealant is manufactured by Ocular Therapeutix (Bedford, MA, USA), and has been approved by the US Food and Drug Administration (FDA).

“Receiving approval to commercialize this product is a huge milestone for the company,” said Amar Sawhney, PhD, president and CEO of Ocular Therapeutix. “We expect this novel product will enable surgeons to optimize postoperative care of their patients, and look forward to a successful launch in the United States.”

“Eye surgeons have been waiting for an alternative to suture that is easy to apply, comfortable for the patient, and doesn’t require removal following surgery. Beyond those advantages, the ReSure Sealant has shown itself to be even more effective than suture in sealing corneal incisions against the real-world forces that can cause wound leaks after cataract surgery,” said John Hovanesian, MD, of Harvard Eye Associates (San Clemente, CA, USA), and a principal Investigator in the pivotal clinical trial. “I foresee this device becoming a staple in ophthalmic practices nationwide.”

Cataract surgery is the most commonly performed surgery in the United States, with approximately 3.5 million procedures conducted annually. Clear corneal cataract wound leaks are widely thought to be a contributing factor to postsurgical complications. Presently, ophthalmologists use stromal hydration to close these wounds, but recent reports suggest this method of wound closure may not be adequate to provide a watertight seal.

Related Links:

Ocular Therapeutix
Harvard Eye Associates



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.